United States · Health Care · USD · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average
Amounts in USD; stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Enveric Biosciences, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -304.04% | - | 97.68% | 49.41% | 33.07% | 24.85% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -214.51% | -318.15% | - | - | - | - |
| Total Assets | $5,095,941.00 | $418,450.00 | $418,450.00 | $418,450.00 | $418,450.00 | $418,450.00 |
| Net Income | -$8,771,987.00 | -$8,771,881.00 | -$8,771,881.00 | -$8,771,881.00 | -$8,771,881.00 | -$8,771,881.00 |